Faculty Profiles - HASHIMOTO Shinichi

Papers - HASHIMOTO Shinichi

Division display 41 - 60 of about 115 ／ All the affair displays >>

Tanoue S., Kanmura S., Hinokuchi M., Arima S., Sasaki F., Hashimoto S., Ido A. . Role of apoptosis inhibitor of macrophages in patients with IgG4-related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition . Biomedical Reports17 ( 4 ) 82 2022

Language：Japanese Publisher：Biomedical Reports

Type 1 autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4-related disease (IgG4-RD) and is a unique chronic inflammatory disease characterized by fibrosis. IgG4-RD is caused by an autoimmune mechanism that mimics malignant tumors and inflammatory disorders. Apoptosis inhibitor of macrophages (AIM) can function as a biomarker of autoimmune or inflammatory diseases with tissue fibrosis, including in inflammatory bowel disease and chronic liver disease. Therefore, the aim of the present study was to clarify the role of serum AIM levels and the clinical characteristics of patients with IgG4-RD and AIP. For this purpose, serum AIM concentrations were assessed using ELISA and the association between AIM and the laboratory and clinical data from patients with IgG4-RD/AIP, patients with pancreatic cancer (PC) and healthy controls (HCs), was determined. The results demonstrated that the serum AIM concentrations were not associated with the laboratory data. However, the serum AIM levels were significantly elevated in patients with AIP compared with the HCs and patients with PC. Furthermore, the serum AIM levels significantly decreased following steroid therapy in patients with AIP who were in remission. Overall, the present study demonstrates that serum AIM levels may be a potentially useful biomarker for the differential diagnosis of AIP and for evaluating the therapeutic reactivity of affected patients.

DOI： 10.3892/br.2022.1565

Scopus

PubMed

山里侑, 樋之口真, 柿原敦子, 児島一成, 荒木紀匡, 前田英仁, 田中啓仁, 小牧祐雅, 有馬志穂, 田ノ上史郎, 佐々木文郷, 橋元慎一, 上村修司, 井戸章雄 . 超音波内視鏡下穿刺吸引細胞診(EUS-FNA)で診断し得た腸間膜神経内分泌腫瘍(NET-G3)の1例 . 日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集118回・112回 139 - 139 2021.12

Kozono M., Tanoue S., Kiyama K., Jikuya K., Kawahira M., Hinokuchi M., Iwaya H., Arima S., Hashimoto S., Hiwatashi K., Fukuda Y., Sakoda M., Higashi M., Tokushige K., Ido A. . A case of immunoglobulin G4-related sclerosing mesenteritis without other organ involvement . Clinical Journal of Gastroenterology14 ( 5 ) 1411 - 1418 2021.10

Language：Japanese Publisher：Clinical Journal of Gastroenterology

A 64-year-old man presented to our hospital with abdominal pain and 4–5 episodes of watery diarrhea per day for 2 months. Abdominal ultrasound examination revealed a mass in the peritoneal cavity, and computed tomography showed a 13.4 cm mass in the mesentery and a 3 cm mass in the mesocolon. The patient underwent laparoscopic partial resection for diagnosis. Microscopically, abundant fibrosis and numerous immunoglobulin (Ig) G4-positive plasma cells were observed. The serum level of IgG4 was 665 mg/dl postoperatively. These findings suggested that the lesion was consistent with IgG4-related sclerosing mesenteritis. Oral steroids resulted in rapid disappearance of symptoms and a decrease in masses. Recently, sclerosing mesenteritis are reported as IgG4-related disease or mimicking IgG4-related disease but multiple lesions rarely occur in the same organ. We report a case of IgG4-related sclerosing mesenteritis with multiple lesions without involvement of other organs, such as the pancreas and salivary glands.

DOI： 10.1007/s12328-021-01451-1

Scopus

PubMed

Kozono Masaya, Tanoue Shiroh, Kiyama Kanna, Jikuya Kenichi, Kawahira Machiko, Hinokuchi Makoto, Iwaya Hiromichi, Arima Shiho, Hashimoto Shinichi, Hiwatashi Kiyokazu, Fukuda Yoshio, Sakoda Masahiko, Higashi Michiyo, Tokushige Koichi, Ido Akio . 他臓器侵襲を伴わない免疫グロブリンG4関連硬化性腸間膜炎の1例(A case of immunoglobulin G4-related sclerosing mesenteritis without other organ involvement) . Clinical Journal of Gastroenterology14 ( 5 ) 1411 - 1418 2021.10

Language：English Publisher：シュプリンガー・ジャパン(株)

症例は64歳男性で、2ヵ月前から臍部周辺の腹痛と毎週4～5回の水様便を呈して当院を受診した。身体所見では腹部は軟性で軽度圧痛があり、頻回な腸管運動がみられた。また、臨床検査で軽度貧血、CRPの軽度上昇、可溶性IL-2の増加が認められた。腹部超音波検査にて腹腔内に10cm大の腫瘤が検出され、造影CTでは上腸間膜と横行結腸間膜に軟部組織腫瘤を認め、多発性の小結節が腫瘤周囲に存在していた。このほか、MRI検査にてT1強調像で低信号、脂肪抑制T2強調像で軽度高信号を呈する上腸間膜腫瘤が認められた。なお、造影CTでは他臓器侵襲は確認されず、PET-CTは施行しなかった。腹腔鏡アプローチにて病理診断を行ったところ、術中所見では小腸間膜に腫瘍を認め腹膜腫瘤を形成しており可動性に乏しかった。腫瘍末梢側に多数の黄色結節がみられ、術中迅速病理検査で非定型細胞が検出された。組織診では多量のIgG4陽性形質細胞が中隔に観察され、IgG4関連硬化性腸間膜炎を示唆する所見であった。経口ステロイド療法としてプレドニゾロン0.5mg/kgを開始したところ、下痢と腹部症状は急速に改善し、1ヵ月後には完全消失が得られた。治療開始6ヵ月後、症状の再燃や腫瘤の再増殖は認めていない。

Iwaya H, Kojima I, Hinokuchi M, Hashimoto S, Tanoue S, Kanmura S, Ido A . Novel biliary stenting with an antireflux system for distal biliary obstruction in a patient with a surgically altered anatomy. . Endoscopy international open9 ( 10 ) E1561 - E1562 2021.10

Kuwatani M., Kawakubo K., Sugimori K., Inoue H., Kamada H., Ishiwatari H., Kato S., Iwashita T., Yoshida M., Hashimoto S., Itonaga M., Mizukami Y., Nomura Y., Katanuma A., Sakamoto N. . Trial protocol: A randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable metal stent for biliary drainage during neoadjuvant therapy in patients with pancreatic cancer with obstructive jaundice (PUN-NAC trial) . BMJ Open11 ( 7 ) e045698 2021.7

Language：Japanese Publisher：BMJ Open

Introduction Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy (NAC/NACRT) for resectable/borderline resectable pancreatic cancers was recently performed to improve clinical outcomes and led to good results, although it remains controversial whether NAC/NACRT is beneficial for resectable pancreatic cancer. A few recent studies revealed longer patency and lower cost related to the stent occlusion of a metal stent than those of a plastic stent during NAC/NACRT. It also remains controversial which type of self-expandable metal stent (SEMS) is the most suitable for patients with resectable/borderline resectable pancreatic cancer during NAC/NACRT: an uncovered SEMS (USEMS), a fully covered SEMS (FCSEMS) or a partially covered SEMS (PCSEMS). So far, two randomised controlled trials indicated that a USEMS and an FCSEMS were similar in preoperative stent dysfunction and adverse event rate. Thus, we aimed to verify the non-inferiority of a PCSEMS to a USEMS in this multicentre randomised controlled trial. Methods and analysis We designed a multicentre randomised controlled trial, for which we will recruit 100 patients with resectable/borderline resectable pancreatic cancer and distal biliary obstruction scheduled for NAC/NACRT from 13 high-volume institutions. Patients will be randomly allocated to the PCSEMS group or USEMS group. The primary outcome measure is the preoperative biliary event rate. Data will be analysed after completion of the study. We will calculate the 95% CIs of the incidence of preoperative biliary events in each group and analyse whether the difference between them is within the non-inferiority margin (10%). Ethics and dissemination This study has been approved by the institutional review board of Hokkaido University Hospital. The results will be submitted for presentation at an international medical conference and published in a peer-reviewed journal. Trial registration number UMIN000041737; jRCT1012200002.

DOI： 10.1136/bmjopen-2020-045698

Scopus

PubMed

Taguchi H., Otsuka T., Shimokawa M., Arima S., Hashimoto S., Ido A., Koga F., Ueda Y., Nakazawa J., Komori A., Otsu S., Fukahori M., Makiyama A., Honda T., Shibuki T., Mizuta T., Mitsugi K., Nio K., Ide Y., Ureshino N., Shirakawa T. . Gemcitabine plus nanoparticle albumin-bound paclitaxel versus FOLFIRINOX for recurrent pancreatic cancer after resection . Anticancer Research41 ( 7 ) 3573 - 3582 2021.7

Language：Japanese Publisher：Anticancer Research

Background/Aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection. Patients and Methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed. Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.0 vs. 10.6 months, respectively; p=0.02). However, the difference was not significant on adjusted analysis using the Cox proportional hazards model (adjusted p=0.90). Patients receiving FOLFIRINOX (n=10) and GnP (n=34) in the rPC group had comparable OS (medians, 12.2 vs. 14.4 months, respectively; p=0.82) even after adjusting for covariates using the Cox model (adjusted p=0.18). Conclusion: The outcomes of patients in the rPC and mPC groups were comparable following chemotherapy. Both FOLFIRINOX and GnP may be reasonable options for treating rPC.

DOI： 10.21873/anticanres.15145

Scopus

PubMed

岩田大輝, 樋之口真, 児島一成, 藤野悠介, 川平真知子, 藤田俊浩, 岩屋博道, 有馬志穂, 田ノ上史郎, 蔵原弘, 又木雄弘, 橋元慎一, 東美智代, 大塚隆生, 井戸章雄 . 長期的な経過をたどった膵粘液癌の1例 . 日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集117回・111回 150 - 150 2021.6

Toyodome Koshiro, Taguchi Hiroki, Hinokuchi Makoto, Fujita Toshihiro, Iwaya Hiromichi, Iwashita Yuji, Tanoue Shiroh, Hashimoto Shinichi, Nagata Yuki, Hatanaka Shingo, Higashi Michiyo . A case of communicating accessory bile duct with double cystic ducts and a fibrous polyp in the bile duct . Tando35 ( 2 ) 188 - 196 2021.5

Language：Japanese Publisher：Japan Biliary Association

<p>A 66-year-old woman was referred to our department for the examination of a pancreatic cyst. Endoscopic ultrasonography showed a tumor in the bile duct and another duct communicating with the bile duct. Cholangiography revealed the bile ducts forming a circuit, double cystic ducts, and a defect suspected of the bile duct tumor. Communicating accessory bile ducts (CABDs) and a fibrous polyp were diagnosed based on the imaging and pathological findings. After subtotal stomach-preserving pancreaticoduodenectomy, CABDs were histologically confirmed. We report a rare case of CABD with double cystic ducts and a bile duct fibrous polyp.</p>

DOI： 10.11210/tando.35.188

CiNii Research

豊留孝史郎, 田口宏樹, 樋之口真, 藤田俊浩, 岩屋博道, 岩下祐司, 田ノ上史郎, 橋元慎一, 永田祐貴, 畠中真吾, 東美智代 . 重複胆嚢管様の胆道走行および胆管線維性ポリープを伴った、副交通胆管枝(communicating accessory bile duct)の1例 . 胆道35 ( 2 ) 188 - 196 2021.5

Language：Japanese Publisher：(一社)日本胆道学会

症例は66歳女性.腹部超音波検査で膵頭部嚢胞が疑われ当科を受診した.MRCP,EUSで総胆管および近傍に胆管と思われる管腔構造を認めた.造影EUSでは,胆管内に多血性の低エコー腫瘤を認め,胆管腫瘍の合併も疑われた.胆管造影では,胆管内は隔壁様の構造で隔たれ環状構造を形成しており,副交通胆管枝(communicating accessory bile duct:CABD)と診断した.また,胆嚢管は2本に分岐し,それぞれの胆管に合流し,重複胆嚢管類似の胆道走行を認めた.胆管内には輪郭不整な透亮像を認め,腫瘍生検結果は線維性ポリープであった.亜全胃温存膵頭十二指腸切除術が施行され,術後病理標本では,膵上縁より上流のレベルで重複した胆管上皮を認め,CABDに矛盾しない所見であった.CABDと重複胆嚢管類似の複雑な胆道構造および,胆管線維性ポリープを合併した症例を報告する.(著者抄録)

Language：Japanese Publisher：(一社)日本胆道学会

Kanmura S. . Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis . Clinical and translational gastroenterology12 ( 4 ) e00331 2021.4

Language：Japanese Publisher：Clinical and translational gastroenterology

INTRODUCTION:DEFA1A3 encodes human neutrophil peptides (HNPs) 1-3 and has multiple copy number variations (CNVs). HNPs are associated with innate immunity. Ulcerative colitis (UC), a chronic inflammatory gastrointestinal disorder, is a life-threatening condition, and predictive markers of UC severity are needed. This study investigated the relationship between DEFA1A3 CNV and UC severity.METHODS:This study enrolled 165 patients with UC. The relationship between DEFA1A3 CNV and disease severity was analyzed based on Mayo score, patient characteristics, and treatment methods. In addition, serum and stimulated neutrophil-derived HNP concentrations were also measured in patients with high and low DEFA1A3 CNV.RESULTS:DEFA1A3 CNV was significantly correlated with Mayo score and white blood cell count (R = 0.46, P < 0.0001; R = 0.29, P = 0.003, respectively), and only high copy numbers of DEFA1A3 were independent factors for severe UC (P < 0.001, odds ratio: 1.88, 95% confidence interval, 1.34-2.61). The number of severe UC patients with high DEFA1A3 CNV was significantly greater than those with low CNV. We confirmed the associations between DEFA1A3 and UC severity using a validation cohort. In addition, the HNP concentration in high-copy number patients was significantly higher after neutrophil stimulation than that in low-copy number patients.DISCUSSION:This study demonstrated that there is a correlation between DEFA1A3 copy number and severity in patients with UC. In addition, neutrophils from UC patients with higher DEFA1A3 CNV had high reactivity of secretion of HNPs after stimulation. DEFA1A3 CNV may be a novel severity marker and a potential therapeutic target for UC.

DOI： 10.14309/ctg.0000000000000331

Scopus

PubMed

Iwaya H. . Prognostic significance of extracellular volume fraction with equilibrium contrast-enhanced computed tomography for pancreatic neuroendocrine neoplasms . Pancreatology21 ( 4 ) 779 - 786 2021

Language：Japanese Publisher：Pancreatology

Background: /Objectives: Identifying reliable pretreatment imaging biomarkers for pancreatic neuroendocrine neoplasm (PanNEN) is a key imperative. Extracellular volume (ECV) fraction quantified with equilibrium contrast-enhanced CT can be easily integrated into routine examinations. This study aimed to determine whether ECV fraction with equilibrium contrast-enhanced computed tomography (CECT) could predict long-term outcomes in patients with PanNEN. Methods: This study was a retrospective observational study of 80 patients pathologically diagnosed with PanNEN at a single institution. ECV fraction of the primary lesion was calculated using region-of-interest measurement within PanNEN and the aorta on unenhanced and equilibrium CECT. The impact of clinical factors and tumor ECV fraction on progression-free survival (PFS) and overall survival (OS) was assessed with univariate and multivariate analyses using Cox proportional hazards models. The correlation between WHO classification and tumor ECV fraction was evaluated using Kendall rank correlation coefficients. Results: PFS and OS rates were estimated as 93.4% and 94.6%, 78.7% and 86.2%, 78.7% and 77.0%, and 78.7% and 66.6% at 1, 3, 5, and 10 years, respectively. Multivariate analysis revealed that Union for International Cancer Control (UICC) stage (hazard ratio [HR] = 3.95, P = 0.003), WHO classification (HR = 12.27, P = 0.003), and tumor ECV fraction (HR = 11.93, P = 0.039) were independent predictors of PFS. Patient age (HR = 1.11, P < 0.001), UICC stage (HR = 3.14, P = 0.001), and tumor ECV fraction (HR = 5.27, P = 0.024) were independent significant variables for predicting OS. Tumor ECV fraction had a weak inverse relationship with WHO classification (P = 0.045, τ = −0.178). Conclusions: ECV fraction determined by equilibrium CECT and UICC stage may predict survival in patients with PanNEN.

DOI： 10.1016/j.pan.2021.02.020

Scopus

PubMed

Sasaki F, Kanmura S, Oda K, Maeda H, Kabayama M, Iwaya H, Komaki Y, Arima S, Tanoue S, Hashimoto S, Fujita H, Ido A . Acetaldehyde breath test as a cancer risk marker in patients with esophageal and hypopharyngeal squamous cell carcinoma. . PloS one16 ( 5 ) e0251457 2021

Language：Japanese Publisher：PLoS ONE

Patients with inactive acetaldehyde dehydrogenase 2 (ALDH2) are at high risk for esophageal squamous cell carcinoma (ESCC) and hypopharyngeal squamous cell carcinoma (HPSCC). The acetaldehyde breath test (ABT) may demonstrate ALDH2 gene polymorphisms. We evaluated the usefulness of the ABT in patients with ESCC and HPSCC. The squamous cell carcinoma (SCC) group consisted of 100 patients who were treated with endoscopic submucosal dissection (ESD) for ESCC or HPSCC, and the control group (HC) consisted of 275 healthy subjects. The SCC group comprised the "single subgroup"(n = 63), in which a single lesion was initially treated with ESD, and the "multiple subgroup"(n = 31), in which multiple lesions were initially treated with ESD. First, we compared the groups' risk factors for carcinogenesis and measured the acetaldehyde-to-ethanol (A/E) ratio. Then we tested the groups' differences in the abovementioned carcinogenic risk factors. We found that the proportion of individuals in the SCC group with inactive ALDH2 (A/E ratio ≥ 23.3) was significantly higher than that in the HC group (p = 0.035), as was the A/E ratio (p < 0.001). Also, the proportion of individuals with inactive ALDH2 in the multiple subgroup was significantly higher than that in single subgroup (p = 0.015), as was the A/E ratio (p = 0.008). In conclusion, ABT may be a potential screening tool for detecting people at risk of ESCC and HPSCC. In addition, it could be a useful tool in detecting patients at risk of multiple or double carcinomas among patients with ESCC and HPSCC.

DOI： 10.1371/journal.pone.0251457

Scopus

PubMed

Nakazawa J. . Analysis of factors affecting progression-free survival of first-line chemotherapy in older patients with advanced gastrointestinal cancer . Journal of Geriatric Oncology12 ( 8 ) 1200 - 1207 2021

Language：Japanese Publisher：Journal of Geriatric Oncology

Objectives: Few studies have investigated factors influencing the efficacy of chemotherapy in older patients with cancer. This study aimed to evaluate the usefulness of G8, geriatric assessment (GA), and factors measured in general clinical practice for evaluating progression-free survival (PFS) of first-line palliative chemotherapy in older patients with advanced gastrointestinal cancer. Materials and methods: This was a prospective observational study of older patients (age ≥70 years) with advanced gastrointestinal cancer. The modified cut-off value of G8 was determined by referring to two or more abnormal GA conditions. The usefulness of baseline GA and G8 (conventional and modified cut-off value) was assessed according to the efficacy (PFS and disease control rate) of the administered first-line palliative chemotherapy. Results: Overall, 93 patients were evaluated between March 2017 and February 2019. A modified G8 cut-off value of ≤12 had a sensitivity and specificity of 68.9% and 46.9%, respectively. PFS was significantly prolonged in the patients with G8 > 12, serum albumin ≥3.5 g/dl, and in whom grade ≥3 adverse events occurred. There was no significant difference in the PFS between monotherapy and combination therapy. GA was not useful for predicting PFS prolongation or the occurrence of serious adverse events in first-line treatment. Conclusion: Among older patients with advanced gastrointestinal cancer who receive first-line chemotherapy, a modified G8 cut-off value of 12 points, occurrence of grade 3 or higher adverse events, albumin levels, rather than age or performance status were predictors of PFS prolongation.

DOI： 10.1016/j.jgo.2021.05.006

Scopus

PubMed

矢野弘樹, 橋元慎一, 田口宏樹, 田ノ上史郎, 岩屋博道, 有馬志穂, 佐々木文郷, 上村修司, 東美智代, 井戸章雄 . 膵体部癌との鑑別に難渋し、切除標本により診断し得た2型自己免疫性膵炎の1例 . 膵臓35 ( 5 ) 447 - 454 2020.10

Publisher：(一社)日本膵臓学会

症例は46歳女性.心窩部痛,嘔気を主訴に受診した.膵酵素の上昇を認め,急性膵炎の診断で保存的に加療された.画像所見で膵体尾部実質の不均一な造影効果と尾側膵管の拡張を認め,膵腫瘍が疑われた.EUS-FNAにおける組織診断で確定診断が得られなかったが,膵体部癌の可能性が否定できず,手術治療を行った.切除標本にて特徴的な組織所見を示し,2型自己免疫性膵炎の診断に至った.(著者抄録)

Nishikoba N. . HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression . Frontiers in Immunology11 2135 2020.9

Sasaki S, Hashimoto S, Yamamoto K, Sakaida I . Olmesartan-associated Enteropathy Mimics Endoscopic Findings of Celiac Disease. . Internal medicine (Tokyo, Japan)59 ( 14 ) 1777 - 1778 2020.7

笠井亜衣, 橋元慎一, 恒吉研吾, 樺山雅之, 岩屋博道, 有馬志穂, 田口宏樹, 上村修司, 東美智代, 井戸章雄 . 膵臓の腫瘤性病変に対するEUS-FNAで診断に至ったB細胞リンパ腫の3例 . 膵臓35 ( 2 ) 213 - 221 2020.4

Publisher：(一社)日本膵臓学会

膵原発の悪性リンパ腫は,節外性悪性リンパ腫の2%以下,膵悪性腫瘍の0.5%未満と稀である.画像所見のみでは鑑別が難しく,病理組織学的評価による正確な診断が重要である.今回,膵腫瘤に対し超音波内視鏡下穿刺吸引法(EUS-FNA)でB細胞リンパ腫と診断した3例を経験し,うち2例は化学放射線療法で改善した.EUS-FNAは,リンパ腫の病型診断および治療方針決定に有用と考えられた.(著者抄録)

Kurita A. . Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study) . Gastrointestinal Endoscopy91 ( 2 ) 373 - 381.e2 2020.2

　 PREV - NEXT 　

< HASHIMOTO Shinichi>

Papers - HASHIMOTO Shinichi